海翔药业(002099)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002099 海翔药业

已收盘 12-25 15:00:00

{"stockData":{"symbol":"002099","market":"SZ","secType":"STK","nameCN":"海翔药业","latestPrice":6.11,"timestamp":1766646198000,"preClose":6.02,"halted":0,"volume":19247800,"delay":0,"changeRate":0.015,"floatShares":1616000000,"shares":1619000000,"eps":-0.207,"marketStatus":"已收盘","change":0.09,"latestTime":"12-25 15:00:00","open":6.02,"high":6.27,"low":5.95,"amount":117000000,"amplitude":0.0532,"askPrice":6.11,"askSize":236,"bidPrice":6.1,"bidSize":1282,"shortable":0,"etf":0,"ttmEps":-0.207,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766712600000},"marketStatusCode":5,"adr":0,"adjPreClose":6.02,"symbolType":"stock","openAndCloseTimeList":[[1766626200000,1766633400000],[1766638800000,1766646000000]],"highLimit":6.62,"lowLimit":5.42,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1618715253,"isCdr":false,"pbRate":1.9,"roa":"--","roe":"0.14%","epsLYR":-0.21,"committee":-0.561486,"marketValue":9890000000,"turnoverRate":0.0119,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-12-29。","floatMarketCap":9872000000},"requestUrl":"/m/hq/s/002099","defaultTab":"news","newsList":[{"id":"2593349840","title":"海翔药业：截止12月19日公司股东人数为27172人","url":"https://stock-news.laohu8.com/highlight/detail?id=2593349840","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593349840?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:31","pubTimestamp":1766478670,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)12月23日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止2025年12月20日股东人数是多少？海翔药业回复：您好，截止12月19日公司股东人数为27172人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300023606.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","002099","BK0239","BK0192","BK0028","BK0188"],"gpt_icon":0},{"id":"2592787905","title":"海翔药业：研发经费分期支付不构成重大影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2592787905","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592787905?lang=zh_cn&edition=full","pubTime":"2025-12-18 20:51","pubTimestamp":1766062270,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业12月17日在投资者关系平台上答复投资者关心的问题。海翔药业回复：您好，根据《合作协议》规定，在合作期限内，研发经费将根据具体的合作项目按进度分期支付，不会对公司2025年度的财务状况、经营成果构成重大影响。国科大杭高院相关研究团队此前与产业界已有科研成果转化的成功案例，实际贡献经济效益。根据《深圳证券交易所股票上市规则》，公司目前不存在任何触及退市风险的情形。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800035339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0239","BK0028","BK0077","BK0188","002099"],"gpt_icon":0},{"id":"2592995768","title":"海翔药业(002099.SZ)：NWRD08注射液完成Ⅱ期临床首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2592995768","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592995768?lang=zh_cn&edition=full","pubTime":"2025-12-17 17:58","pubTimestamp":1765965522,"startTime":"0","endTime":"0","summary":"公告显示，NWRD08注射液是我国自主研发的首个针对HPV16/18阳性宫颈高级别鳞状上皮内病变进入Ⅱ期临床阶段的新一代治疗性核酸药物，其通过激活特异性T细胞免疫清除感染细胞。与预防性HPV疫苗不同，其专门针对已感染HPV并出现相关病变的患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海翔药业(002099.SZ)：NWRD08注射液完成Ⅱ期临床首例受试者入组","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0028","002099","BK0077","BK0192","BK0239"],"gpt_icon":0},{"id":"2590567748","title":"海翔药业：截止12月10日公司股东人数为27495人","url":"https://stock-news.laohu8.com/highlight/detail?id=2590567748","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590567748?lang=zh_cn&edition=full","pubTime":"2025-12-11 15:07","pubTimestamp":1765436843,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)12月11日在投资者关系平台上答复投资者关心的问题。投资者提问：截至12月10日股东人数为多少？海翔药业回复：您好，截止12月10日公司股东人数为27495人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100019054.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002099","BK0188","BK0077","BK0239","BK0192"],"gpt_icon":0},{"id":"2590464903","title":"海翔药业：公司目前经营情况正常且现金流健康稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=2590464903","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590464903?lang=zh_cn&edition=full","pubTime":"2025-12-09 20:51","pubTimestamp":1765284677,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)12月08日在投资者关系平台上答复投资者关心的问题。投资者提问：1，公司目前现金流情况，后续并购项目的考虑？2，公司行业整体情况以及公司在手订单情况？请详告。海翔药业回复：您好，公司目前经营情况正常且现金流健康稳健，未来如有并购相关计划，将严格按照相关法律法规及时履行信息披露义务。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900037416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","159399","BK0192","BK0077","002099","BK0028"],"gpt_icon":0},{"id":"2590316879","title":"海翔药业(002099.SZ)拟与杭高院共建先进合成技术产业研究院","url":"https://stock-news.laohu8.com/highlight/detail?id=2590316879","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590316879?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:18","pubTimestamp":1765268289,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海翔药业(002099.SZ)公告，公司与国科大杭州高等研究院(简称“杭高院”)签署了《共建先进合成技术产业研究院合作协议》，产业研究院的研发方向主要聚焦医药原料药、中间体、染料、新材料的开发与工业化等，合作总金额5000万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海翔药业(002099.SZ)拟与杭高院共建先进合成技术产业研究院","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0192","BK0028","BK0239","002099","BK0077"],"gpt_icon":0},{"id":"2589338424","title":"海翔药业：生产基地主要分布在台州地区","url":"https://stock-news.laohu8.com/highlight/detail?id=2589338424","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589338424?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:15","pubTimestamp":1765181715,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)12月08日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司目前的产能分布及产能利用率情况？海翔药业回复：您好，公司目前生产基地主要分布在台州地区，当前生产经营活动正常有序，在手订单储备与客户需求节奏相匹配，产能利用率维持在合理水平。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800015519.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0188","BK0239","002099","BK0077","BK0028"],"gpt_icon":0},{"id":"2588742084","title":"海翔药业：截止11月28日公司股东人数为27406人","url":"https://stock-news.laohu8.com/highlight/detail?id=2588742084","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588742084?lang=zh_cn&edition=full","pubTime":"2025-12-01 15:57","pubTimestamp":1764575835,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)12月01日在投资者关系平台上答复投资者关心的问题。投资者提问：截至11月28日公司的股东人数为多少？海翔药业回复：您好，截止11月28日公司股东人数为27406人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100013550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0028","BK0239","002099","BK0188","BK0077"],"gpt_icon":0},{"id":"2586023425","title":"海翔药业：参投基金持有天兵科技1.352%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2586023425","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586023425?lang=zh_cn&edition=full","pubTime":"2025-11-26 16:33","pubTimestamp":1764145990,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业11月26日在投资者关系平台上答复投资者关心的问题。海翔药业回复：您好，公司参投的寓鑫基金持有天兵科技1.352%股权，该基金投资项目还涉及航天航空材料、金属新材料、医药研发、高端设备制造、芯片制造等领域。此外公司投资设立的产业基金北京国信海翔参投了部分创新药项目，涉及HPV感染及肝癌治疗性疫苗、TCR-T细胞治疗、重组巴曲酶等领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600021931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0192","BK0028","BK0188","002099"],"gpt_icon":0},{"id":"2585113335","title":"海翔药业：截止11月20日公司股东人数为27726人","url":"https://stock-news.laohu8.com/highlight/detail?id=2585113335","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585113335?lang=zh_cn&edition=full","pubTime":"2025-11-21 16:36","pubTimestamp":1763714174,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)11月21日在投资者关系平台上答复投资者关心的问题。投资者提问：截至11月20日公司股东人数为多少？海翔药业回复：您好，截止11月20日公司股东人数为27726人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100021097.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099","BK0077","BK0192","BK0239","BK0028","BK0188"],"gpt_icon":0},{"id":"2584095654","title":"海翔药业（002099）披露2025年第一次临时股东大会决议公告，11月18日股价下跌0.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584095654","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584095654?lang=zh_cn&edition=full","pubTime":"2025-11-18 22:43","pubTimestamp":1763476998,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘，海翔药业报收于6.31元，较前一交易日下跌0.94%，最新总市值为102.14亿元。近日，浙江海翔药业股份有限公司发布2025年第一次临时股东大会决议公告。公告显示，公司于2025年11月18日召开2025年第一次临时股东大会，审议通过了董事会换届选举议案，选举王扬超、许国睿、姚冰、陈光顺、陈方琪为第八届董事会非独立董事，俞永平、钱建民、梁超为独立董事。会议召集召开程序合法，表决结果有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800040276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0239","BK0028","BK0192","002099"],"gpt_icon":0},{"id":"2583258099","title":"海翔药业：截止11月10日股东人数为28546人","url":"https://stock-news.laohu8.com/highlight/detail?id=2583258099","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583258099?lang=zh_cn&edition=full","pubTime":"2025-11-13 08:57","pubTimestamp":1762995426,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)11月12日在投资者关系平台上答复投资者关心的问题。投资者提问：截至11月10日公司的股东人数为多少？海翔药业回复：您好，截止11月10日公司股东人数为28546人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300008341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0028","BK0188","002099","BK0077","BK0239"],"gpt_icon":0},{"id":"2581081137","title":"股市必读：海翔药业（002099）11月5日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2581081137","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581081137?lang=zh_cn&edition=full","pubTime":"2025-11-06 08:07","pubTimestamp":1762387620,"startTime":"0","endTime":"0","summary":"h2,h3,h4{padding: 10px 0;font-size: 16px;line-height: 30px;color:#262626;font-weight: 600;}h2{border-bottom: 1px solid #d8dee4; padding-bottom: 0.3em}.article_content ul{padding-left:22px;}截至2025年11月5日收盘，海翔药业报收于6.34元，上涨1.6%，换手率2.15%，成交量34.71万手，成交额2.18亿元。　　来自交易信息汇总：11月5日主力资金净流入691.55万元，显示主力对海翔药业股票的积极介入。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251106/31771339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0188","BK0192","BK0239","BK0077","002099","BK0028"],"gpt_icon":0},{"id":"2581749227","title":"海翔药业：截止10月31日公司股东人数为27574人","url":"https://stock-news.laohu8.com/highlight/detail?id=2581749227","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581749227?lang=zh_cn&edition=full","pubTime":"2025-11-05 16:33","pubTimestamp":1762331591,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)11月05日在投资者关系平台上答复投资者关心的问题。投资者提问：截至10月30日公司的股东人数为多少？海翔药业回复：您好，截止10月31日公司股东人数为27574人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500027637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0188","BK0028","BK0077","BK0239","002099"],"gpt_icon":0},{"id":"2580694722","title":"11月3日海翔药业（002099）涨停分析：治理优化、产品提价、研发驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2580694722","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580694722?lang=zh_cn&edition=full","pubTime":"2025-11-03 15:31","pubTimestamp":1762155107,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业11月3日涨停收盘，收盘价6.31元。今日海翔药业涨停的可能因素有：1. 公司治理结构优化取得进展，包括董事会换届、管理制度修订及股份回购计划完成87%，提振市场信心；2. 核心产品克林霉素价格回升及培南系列价格企稳，叠加染料业务扭亏为盈，推动毛利率改善；3. 疫苗研发合作项目持续推进，联苯双酯原料药生产销售及肝胆领域在研项目强化医药业务布局；4. 化学制药板块整体活跃形成联动效应。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300015087.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0239","BK0077","002099","BK0192"],"gpt_icon":0},{"id":"2579155736","title":"股市必读：海翔药业三季报 - 第三季度单季净利润同比增长73.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579155736","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579155736?lang=zh_cn&edition=full","pubTime":"2025-10-30 07:50","pubTimestamp":1761781835,"startTime":"0","endTime":"0","summary":"截至2025年10月29日收盘，海翔药业报收于5.67元，下跌0.7%，换手率0.63%，成交量10.14万手，成交额5723.37万元。来自业绩披露要点：2025年第三季度主营收入同比增长8.82%，但单季度归母净利润仍为亏损680.34万元。来自公司公告汇总：监事会审议通过《2025年第三季度报告》及部分募投项目延期议案，项目延期不涉及实施主体和募集资金用途变更。股本股东变化股东户数变动近日海翔药业披露，截至2025年10月20日公司股东户数为2.77万户，较10月10日增加209.0户，增幅为0.76%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000007751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099"],"gpt_icon":0},{"id":"2579995513","title":"图解海翔药业三季报：第三季度单季净利润同比增长73.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579995513","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579995513?lang=zh_cn&edition=full","pubTime":"2025-10-29 03:01","pubTimestamp":1761678085,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业2025年三季报显示，公司主营收入13.67亿元，同比下降5.39%；归母净利润729.03万元，同比下降39.15%；扣非净利润501.05万元，同比下降72.75%；其中2025年第三季度，公司单季度主营收入4.41亿元，同比上升8.82%；单季度归母净利润-680.34万元，同比上升73.96%；单季度扣非净利润-1427.28万元，同比下降14.53%；负债率29.77%，投资收益1018.82万元，财务费用-948.06万元，毛利率25.98%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900003300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099"],"gpt_icon":0},{"id":"2578963041","title":"海翔药业（002099）披露部分募投项目延期公告，10月28日股价上涨0.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578963041","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578963041?lang=zh_cn&edition=full","pubTime":"2025-10-28 22:22","pubTimestamp":1761661331,"startTime":"0","endTime":"0","summary":"截至2025年10月28日收盘，海翔药业报收于5.71元，较前一交易日上涨0.35%，最新总市值为92.43亿元。该股当日开盘5.7元，最高5.76元，最低5.67元，成交额达4908.75万元，换手率为0.53%。公司近日发布公告称，第七届监事会第十次会议于2025年10月27日以通讯表决方式召开，会议审议通过《关于部分募投项目延期的议案》。该项议案已获监事会全票通过。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800043057.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0188","BK0239","002099","BK0077","BK0028"],"gpt_icon":0},{"id":"2577844999","title":"海翔药业：截止10月20日公司股东人数为27682人","url":"https://stock-news.laohu8.com/highlight/detail?id=2577844999","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577844999?lang=zh_cn&edition=full","pubTime":"2025-10-21 15:45","pubTimestamp":1761032726,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)10月21日在投资者关系平台上答复投资者关心的问题。投资者提问：截止10月20日公司的股东人数为多少？海翔药业回复：您好，截止10月20日公司股东人数为27682人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102100020104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0188","BK0028","BK0077","BK0239","002099"],"gpt_icon":0},{"id":"2575410963","title":"股市必读：海翔药业（002099）10月10日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2575410963","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575410963?lang=zh_cn&edition=full","pubTime":"2025-10-13 04:54","pubTimestamp":1760302453,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘，海翔药业报收于5.85元，上涨0.0%，换手率0.85%，成交量13.67万手，成交额8057.11万元。来自：截至2025年9月30日，海翔药业已累计回购股份4,410,000股，占公司总股本的0.27%，成交总金额达26,090,960.52元。回购资金总额不低于15,000万元（含），不超过30,000万元（含），回购价格不超过7.46元/股（含），实施期限为董事会审议通过之日起12个月内。公司回购行为符合相关法规及既定方案。后续将根据市场情况继续实施回购，并按规定履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101300001666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0192","BK0028","002099","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766652435152,"stockEarnings":[{"period":"1week","weight":0.0326},{"period":"1month","weight":0},{"period":"3month","weight":0.047},{"period":"6month","weight":0.0926},{"period":"1year","weight":0.1358},{"period":"ytd","weight":0.1667}],"compareEarnings":[{"period":"1week","weight":0.0183},{"period":"1month","weight":0.0272},{"period":"3month","weight":0.0227},{"period":"6month","weight":0.1509},{"period":"1year","weight":0.1613},{"period":"ytd","weight":0.1758}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江海翔药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"27172人(较上一季度减少1.17%)","perCapita":"59461股","listingDate":"2006-12-26","address":"浙江省台州市椒江区外沙支路100号","registeredCapital":"161871万元","survey":"　　浙江海翔药业股份有限公司的主营业务是医药及染料全产业链业务。公司的主要产品是原料药及医药中间体、合同定制业务、制剂、染料及染颜料中间体。公司已承担完成国家级项目13项，省级项目35项，拥有国内发明专利61项、PCT专利4项，荣获浙江省级科技奖项11项。","listedPrice":11.56},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海翔药业(002099)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海翔药业(002099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海翔药业,002099,海翔药业股票,海翔药业股票老虎,海翔药业股票老虎国际,海翔药业行情,海翔药业股票行情,海翔药业股价,海翔药业股市,海翔药业股票价格,海翔药业股票交易,海翔药业股票购买,海翔药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海翔药业(002099)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海翔药业(002099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}